Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 11/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 11/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 11/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 10/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.70 |
| ▸ | BRD4 | O60885 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 1/20 | 0.70 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.60 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PTAFR | P25105 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724655 | 0.88 | GABRA1 (0.82) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL7717650 | 0.87 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL2874506 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL2843071 | 0.86 | GABRA1 (0.75) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL3142799 | 0.85 | GABRA1 (0.74) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| Alprazolam SCHEMBL16922178 | 0.82 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL8250450 | 0.82 | GABRA1 (0.74) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| Alprazolam SCHEMBL8398 | 0.82 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL10696328 | 0.82 | GABRA1 (0.78) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| Alprazolam SCHEMBL5480614 | 0.82 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47475-E1 | Selective agents for pain suppression | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-RE47475-E1 | Selective agents for pain suppression | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-7119196-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| EP-1490344-A2 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | Wisys Technology Foundation, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-29 | — | — | US | disclosed |
| WO-2003082832-A2 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-20100317619-A1 | Selective Agents for Pain Suppression | CNR2, CNR1, OPRL1 | GABRA1 12/4885GABRA5 5/4885GABRA2 9/4885 |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | GABRE, GABRA6, GABRA5 | GABRA1 4/4885GABRA5 3/4885GABRA2 9/4885 |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | GABRA1 5/4885GABRA5 6/4885GABRA2 4/4885 |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | GABRA1 4/4885GABRA5 1/4885GABRA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.